Hydromorphone Pediatric Dose — Pain Management
Hydromorphone is a potent semi-synthetic opioid analgesic that acts as a full agonist at mu-opioid receptors, producing analgesia through central and peripheral pain pathway modulation. It is approximately 5–7 times more potent than morphine on a milligram-per-milligram basis. In pediatric practice, hydromorphone is used for moderate-to-severe acute pain management when opioid analgesia is indicated, including postoperative pain, procedural pain, and pain associated with serious illness.
Pediatric Dosing
| Route | Dose | Frequency |
|---|---|---|
| Intravenous (IV) | 0.015 mg/kg/dose | Every 4 hours PRN |
| Oral (PO) | 0.03–0.08 mg/kg/dose | Every 4 hours PRN |
For comparison, the adult dose is 0.2–0.6 mg IV every 4 hours PRN or 1–2 mg PO every 4 hours PRN. Pediatric per-kg doses should not exceed adult dose ranges; consult institutional protocol for weight-based maximum dose thresholds.
Worked example — IV route (20 kg child): 20 kg × 0.015 mg/kg = 0.30 mg IV per dose every 4 hours PRN.
Worked example — PO route (20 kg child): 20 kg × 0.03 mg/kg = 0.60 mg PO (low end) to 20 kg × 0.08 mg/kg = 1.60 mg PO (high end) per dose every 4 hours PRN.
Indications and Clinical Context
Hydromorphone is indicated for the management of moderate-to-severe pain in pediatric patients when non-opioid analgesics are insufficient. Common clinical contexts include postoperative analgesia, vaso-occlusive pain crises in sickle cell disease, oncologic pain, and acute pain management in the emergency department or inpatient setting. Its relatively shorter duration of action and high potency make careful dose titration essential in pediatric populations.
Opioid selection and dosing should follow institutional multimodal analgesia protocols. The IV route is preferred in the acute inpatient or ED setting when rapid, titratable analgesia is required. The oral route is appropriate for stable patients who can tolerate oral medications, noting the oral bioavailability is lower than IV, reflected in the higher per-kg PO dose range.
Administration and Monitoring
The IV dose should be administered as a slow push over 2–3 minutes to minimize the risk of hypotension and histamine-related adverse effects. Continuous pulse oximetry and respiratory rate monitoring are recommended during IV opioid administration. Key adverse effects to monitor include respiratory depression, excessive sedation, hypotension, nausea, vomiting, and urinary retention. Naloxone and resuscitative equipment should be readily available whenever IV opioids are administered.
- Avoid use in patients with known hypersensitivity to hydromorphone or other opioids.
- Use with caution in patients with respiratory compromise, hepatic impairment, or concurrent CNS depressant use.
- For patients at or approaching adult weight, apply adult dose caps; consult institutional protocol.
- Reassess pain scores and sedation level before each PRN redose.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.